INNSBRUCK, AUSTRIA— MED-EL Elektromedizinische Geräte GmbH , a global leader in hearing implant solutions, has announced the acquisition of two gene therapy programs from Rescue Hearing Inc . The programs address genetic disorders associated with mutations in the MYO7A and STRC genes....
Continue reading at Hearing Tracker
✦ The floor
Discussion
Signed responses from readers of the wire.
No actionable clinical change — gene therapy for hearing loss remains in early-stage research and has no immediate impact on current audiological practice.
MED-EL's strategic acquisition signals that major implant manufacturers are beginning to invest in biological hearing restoration, potentially reshaping the long-term competitive and treatment landscape in audiology.
- 01MED-EL has acquired two gene therapy programs from Rescue Hearing Inc.
- 02The acquisition expands MED-EL's research portfolio beyond device-based hearing solutions.
- 03Gene therapy approaches aim to restore hearing by targeting genetic causes of hearing loss.
- 04No clinical timeline or pipeline stage for the acquired programs was disclosed.
- 05This follows a broader industry trend of device makers investing in biological hearing treatments.
MED-EL has acquired two gene therapy programs from Rescue Hearing Inc. to expand its research into genetic approaches to hearing restoration.
press releasesupported
